Table 2 Changes in B cells in the TME after ICI treatment in responders

Melanoma

Nivolumab, Ipilimumab

41

High proportion of class-switched memory B cells, activated B cells and GC-like B cells

BCR types, B-cell RNA signatures

[75]

Melanoma

Nivolumab, Ipilimumab

64

Higher memory B cells and naive B cells

Clonal BCR repertoire, IgG

[96]

RCC

Nivolumab, Ipilimumab

59

Higher plasma cells

IgG

[46]

NSCLC

Atezolizumab

344

Higher B cells and plasma cells

TLSs

[85]

NSCLC

Anti-PD-1 treatment

12

CD20+CD22+ADAM28+ B cells in TLSs

-

[100]

NSCLC

Nivolumab

150

-

IgM+ memory B cells in peripheral blood

[99]

Cervical cancer

Anti-PD-1 treatment

8

Higher B cells

Higher expression of PD-L1

[97]

HCC

Cabozantinib combined with Nivolumab

15

Higher B cells, CD138+ B cells

Higher TNF-α expression and TLSs

[98]

SCC (Mouse model)

Anti-PD-L1 treatment

-

B cells

IgM, IgG

[101]

BC (Mouse model)

Anti-PD-1 and CTLA-4 treatment

-

Class-switched plasma cells

IgG

[93]